Latest Biotechnology News

Argenica Therapeutics has reported compelling preclinical data showing ARG-007 significantly reduces brain cell damage and inflammation in moderate traumatic brain injury, matching levels seen in uninjured controls. This reinforces ARG-007’s potential as a breakthrough neuroprotective therapy.

Rhythm Biosciences has fast-tracked the integration of the geneType™ business, restoring full commercial capabilities ahead of schedule and setting the stage for expanded market reach.

Noxopharm has successfully completed key in vitro safety tests for its SOF-SKN™ lupus drug, paving the way for the upcoming HERACLES Phase 1 clinical trial.

Biotron Limited reported a robust net cash inflow of $1.095 million for the December 2024 quarter, driven largely by government grants, supporting its operational stability despite ongoing R&D expenses.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.

Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.

Skin Elements Limited reports steady progress in commercialising its plant-based SE Formula biotechnology, highlighted by ongoing product trials, a successful R&D rebate, and a $513k non-renounceable entitlement issue.

BPH Global Limited secured $325,000 in funding during the December quarter, progressing its Indonesian seaweed venture and renewing key R&D partnerships. The company ends the quarter with $226,000 cash on hand and plans a $1 million capital raise at an upcoming EGM.

Avenira Limited finalised a $4.5 million strategic investment from Hebang Biotechnology and progressed key development milestones at its Wonarah Phosphate Project, signalling a focused push towards near-term production and long-term growth.

Hexima Limited has called off its planned acquisition of AI developer Real Thing Entertainment, ending the quarter with $1.64 million in cash and a cautious outlook on future strategic moves.

Clean TeQ Water Limited reports a landmark $11 million contract for its PHOSPHIX® phosphate removal plant in Ireland, alongside successful project deliveries and lithium recovery breakthroughs, setting the stage for improved financial performance in 2025.

Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.